search
Back to results

Biomarker-guided Intervention to Prevent Acute Kidney Injury (BigpAK-2)

Primary Purpose

Acute Kidney Injury

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Comprehensive Implementation of the Bundle recommended by the "Kidney Disease: Improving Global Outcomes Group" (KDIGO bundle)
Sponsored by
University Hospital Muenster
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Acute Kidney Injury focused on measuring biomarker

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients after major non-cardiac surgery who need to be admitted to the ICU
  • Age > 18 years
  • [TIMP-2]*[IGFBP7] ≥ 0.3 4-18 hours after surgery
  • Inserted jugular central venous line and a urinary catheter
  • Written informed consent.

  • At least one additional risk factor for AKI

    1. Age > 75 years
    2. Critical illness such as ongoing requirement of vasopressor support and/or mechanical ventilation postoperatively
    3. Pre-existing chronic kidney disease (eGFR<60ml/min)
    4. Intraoperative use of radio contrast agents.

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Pre- existing high stages of chronic kidney disease (stage 4 or 5 i.e. eGFR < 15 ml/ min)
  • Kidney transplant within the last 12 month
  • Known (Glomerulo-) Nephritis, interstitial nephritis or vasculitis
  • Anuria at inclusion time
  • Preexisting AKI
  • Renal replacement therapy (RRT) within the last 90 days
  • Indication for renal replacement at the time of inclusion
  • Participation in another intervention trial that investigates a drug/intervention that affects kidney function
  • Persons held in an institution by legal or official order
  • Persons with any kind of dependency on the investigator or employed by the responsible institution or investigator

Sites / Locations

  • Clinical Research Department, Centre Hospitalier Universitaire Brugmann
  • Centre Hospitalier Universitaire de Angers
  • Centre Hospitalier Universitaire de Clermont-Ferrand
  • Service d´Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon
  • Centre Hospitalier Universitaire de Reims
  • Department of Anesthesiology and Intensive Care Medicine, University Hospital Augsburg
  • Department of Anaesthesiology and Intensive Care Medicine, Klinikum Bayreuth GmbH
  • Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus, Ruhr University BochumRecruiting
  • Department of Anesthesiology and Intensive Care Medicine, University Hospital BonnRecruiting
  • Department of Anesthesiology, Intensive Care and Pain Medicine, Klinikum Dortmund
  • Department of Anesthesiology and Intensive Care Medicine, University Hospital "Carl Gustav Carus", Technische Universität Dresden
  • Department of Anesthesiology, University Hospital Düsseldorf, Heinrich-Heine-University DuesseldorfRecruiting
  • Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-EssenRecruiting
  • Department of Anesthesiology, University Medical Center, Georg-August-University
  • Department of Anesthesiology, Heidelberg University HospitalRecruiting
  • Department of Nephrology, Heidelberg University Hospital
  • Department of Anesthesiology and Intensive Care Medicine, Medical Faculty and University Hospital Cologne, University of Cologne
  • Department of Anesthesiology and Intensive Care Medicine, Philipps-UniversityRecruiting
  • Department of Anaesthesiology, Intensive Care and Pain Medicine, University HospitalRecruiting
  • Department of Anesthesiology, Department of Anesthesiology and Critical Care, Franziskus Hospital MünsterRecruiting
  • Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Eberhard Karls University TübingenRecruiting
  • IRCCS Azienda Ospedaliero-Universitaria di BolognaRecruiting
  • Department of Translational Medicine and for Romagna, St. Anne's Archbishop Hospital, University of FerraraRecruiting
  • Department of Health Sciences, Section of Anesthesiology, Intensive Care and Pain Medicine, University of Florence; Department of Anesthesia and Intensive Care, Section of Oncological Anesthesia and Intensive care, Azienda Ospedaliero CareggiRecruiting
  • Department of Anesthesiology and Intensive Care, IRCCS Humanitas Clinical and Research Hospital
  • Santa Chiara Regional Hospital, APSS Trento
  • Department of Anesthesiology and Intensive Care, San Bortolo HospitalRecruiting
  • Department of Anaesthesiology, Laboratory of Experimental Intensive Care and Anaesthesiology (L.E.I.C.A.), Amsterdam UMC, Location Academic Medical Centre (AMC), Amsterdam, University of Amsterdam
  • Department of Anaesthesiology and Intensive Care Medicine, Parc de Salut MarRecruiting
  • Department of Anesthesiology and Critical Care, University Hospital Vall d'Hebron
  • Hospital de IgualadaRecruiting
  • Department of Anesthesia, Hospital Juan Ramon Jimenez
  • Department of Anesthesia and Perioperative Care, Infanta Leonor University HospitalRecruiting
  • Department of Anesthesiology, Hospital Universitario Ramón y CajalRecruiting
  • Hospital 12 de OctubreRecruiting
  • Hospital Clínico San Carlos de MadridRecruiting
  • Servicio de Anestesiologia y Reanimación, Hosp. Universitario de La PrincesaRecruiting
  • Department of Anaesthesiology and Surgical Critical Care, Hospital Universitario Marqués de Valdecilla
  • Hospital Universitario Virgen MacarenaRecruiting
  • Servicio de Anestesiologia, Hospital Universitario y Politécnico La Fe
  • Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV)Recruiting
  • Centre for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Sciences, Queen's University BelfastRecruiting
  • Intensive Care Unit, Royal Surrey County HospitalRecruiting
  • Department of Anaesthetics and Critical Care, Harefield HospitalRecruiting
  • Intensive Care Unit, Royal Liverpool University Hospital
  • Department of Anesthetics, King's College Hospital, Denmark Hill
  • Department of Critical Care, King's College London, Guy's & St Thomas' HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Intervention group

Control group

Arm Description

Outcomes

Primary Outcome Measures

Occurence of moderate or severe AKI

Secondary Outcome Measures

Adherence to the implementation of the KDIGO-bundle
Number of patients in whom Nephrotoxic agents were discontinued Optimal volume status and perfusion pressure were ensured The use of hemodynamic monitoring was considered Serum creatinine and urine output were considered Hyperglycemia was avoided Alternatives to radiocontrast were considered
Severity of AKI
Severity of AKI as defined by the KDIGO guidelines based on creatinine or urine output parameter: Stage 1 Creatinine: 1.5-1.9 times baseline OR > 0.3 mg/dl (> 26.5 mmol/l) increase and/or urine output < 0.5 ml/kg/h for 6-12 hours Stage 2 Creatinine: 2.0-2.9 times baseline and/or urine output < 0.5 ml/kg/h for >= 12 hours Stage 3 Creatinine: 3.0 times baseline OR Increase in serum creatinine to >= 4.0 mg/dl (>= 353.6 mmol/l) OR Initiation of renal replacement therapy OR, In patients < 18 years, decrease in eGFR to < 35 ml/min per 1.73 m2 and/or urine output < 0.3 ml/kg/h for >= 24 hour
Changes in biomarker values
Difference between the 12 h after initial measuring and the initial measuring [TIMP-2]*[IGFBP7] value
Free-days of mechanical ventilation
Free-days of vasopressors
Need of renal replacement therapy
Need of renal replacement therapy
Duration of renal replacement therapy
Duration of renal replacement therapy
Renal recovery
renal recovery is defined as complete recovery: serum creatinine levels < 0.5 mg/dl higher than baseline serum creatinine (creatinine level before surgery), partial recovery: serum creatinine > 0.5 mg/dl higher than baseline but not dialysis-dependence; non-recovery: patients who remained dialysis dependent
Mortality
Mortality
ICU and hospital stay
Major adverse kidney events (MAKE)
- major adverse kidney events consisting of mortality, dialysis dependency persistent renal dysfunction (defined as serum creatinine ≥ 2x to baseline value at hospital discharge)

Full Information

First Posted
October 12, 2020
Last Updated
August 15, 2023
Sponsor
University Hospital Muenster
Collaborators
BioMérieux
search

1. Study Identification

Unique Protocol Identification Number
NCT04647396
Brief Title
Biomarker-guided Intervention to Prevent Acute Kidney Injury
Acronym
BigpAK-2
Official Title
Biomarker- Guided Intervention to Prevent Acute Kidney Injury After Major Surgery. A Prospective Randomized Controlled Multicenter Trial (BigpAK-2)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 17, 2020 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
March 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital Muenster
Collaborators
BioMérieux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
There is no specific therapy for acute kidney injury. It is presumed that supportive measures improve the care and outcome of patients with acute kidney injury. The investigators hypothesize that the implementation of a bundle of supportive measures adapted to patients undergoing major surgery reduces the occurrence of AKI. This randomized prospective multicenter trial is needed to investigator whether the implementation of the bundle of measures is effective to prevent AKI in high risk patients undergoing major surgery.
Detailed Description
In earlier studies, interventions to treat acute kidney injury (AKI) were started after a functional damage of the kidneys was already established. However, none of the interventions had an effect in treating AKI. The Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines recommend implementing different measures in patients at high risk for AKI, but the evidence that the implementation of the bundle (consisting of optimization of hemodynamics and perfusion pressure, avoidance of nephrotoxins and hyperglycemia) can prevent AKI is very weak. Biomarkers can be used to identify patients at high risk for AKI after surgery (prior to the development of AKI). The cell-cycle arrest biomarkers, Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) and Insulin-like growth factor-binding protein 7 (IGFBP7), have been demonstrated to have the best predictive performance for the development of AKI after surgery as compared to other biomarkers. In addition, these biomarkers are not influenced by different co-morbidities or other clinical situations. In the BigpAK1 trial, which was a single-center trial, the authors investigated whether a biomarker-guided implementation of the KDIGO guidelines can reduce the occurrence of AKI in patients undergoing major non-cardiac surgery. The results demonstrate that the implementation of the KDIGO bundle in high risk patients for AKI ([TIMP-2]*[IGFBP7] between 0.3 and 2) significantly reduced the occurrence of AKI compared to the standard of care group. However, this was a single center trial which needs to be confirmed in a large trial. Therefore, based on these data, a definitive, prospective, randomized controlled, multicenter study including 1302 surgical patients at high risk for AKI identified by [TIMP-2]*[IGFBP7] will be performed. The goal of this trial is to investigate the effect of the implementation of the KDIGO bundle in patients at high risk for AKI after major surgery compared to standard of care in the same patient population. This biomarker-guided approach (individualized therapy) enables to treat patients at high risk for AKI prior to a functional damage of the kidneys.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Kidney Injury
Keywords
biomarker

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
1302 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention group
Arm Type
Experimental
Arm Title
Control group
Arm Type
No Intervention
Intervention Type
Other
Intervention Name(s)
Comprehensive Implementation of the Bundle recommended by the "Kidney Disease: Improving Global Outcomes Group" (KDIGO bundle)
Intervention Description
Implementation of the KDIGO bundle for at least 12 hours discontinuation of all nephrotoxic drugs when possible optimization of volume status and hemodynamic parameters (consideration of a functional hemodynamic monitoring) close monitoring of serum creatinine, fluid balance and urinary output avoidance of hyperglycemia considerations of alternatives to radiocontrast agents discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the perioperative period avoidance of HES, gelatin, and chlorid-rich solutions
Primary Outcome Measure Information:
Title
Occurence of moderate or severe AKI
Time Frame
72 hours after start of intervention
Secondary Outcome Measure Information:
Title
Adherence to the implementation of the KDIGO-bundle
Description
Number of patients in whom Nephrotoxic agents were discontinued Optimal volume status and perfusion pressure were ensured The use of hemodynamic monitoring was considered Serum creatinine and urine output were considered Hyperglycemia was avoided Alternatives to radiocontrast were considered
Time Frame
72 hours after start of intervention
Title
Severity of AKI
Description
Severity of AKI as defined by the KDIGO guidelines based on creatinine or urine output parameter: Stage 1 Creatinine: 1.5-1.9 times baseline OR > 0.3 mg/dl (> 26.5 mmol/l) increase and/or urine output < 0.5 ml/kg/h for 6-12 hours Stage 2 Creatinine: 2.0-2.9 times baseline and/or urine output < 0.5 ml/kg/h for >= 12 hours Stage 3 Creatinine: 3.0 times baseline OR Increase in serum creatinine to >= 4.0 mg/dl (>= 353.6 mmol/l) OR Initiation of renal replacement therapy OR, In patients < 18 years, decrease in eGFR to < 35 ml/min per 1.73 m2 and/or urine output < 0.3 ml/kg/h for >= 24 hour
Time Frame
3 days after start of intervention
Title
Changes in biomarker values
Description
Difference between the 12 h after initial measuring and the initial measuring [TIMP-2]*[IGFBP7] value
Time Frame
12 hours after start of intervention
Title
Free-days of mechanical ventilation
Time Frame
up to 3 days after start of intervention
Title
Free-days of vasopressors
Time Frame
up to 3 days after start of intervention
Title
Need of renal replacement therapy
Time Frame
up to 30 days after start of intervention
Title
Need of renal replacement therapy
Time Frame
up to 90 days after start of intervention
Title
Duration of renal replacement therapy
Time Frame
up to 30 days after start of intervention
Title
Duration of renal replacement therapy
Time Frame
up to 90 days after start of intervention
Title
Renal recovery
Description
renal recovery is defined as complete recovery: serum creatinine levels < 0.5 mg/dl higher than baseline serum creatinine (creatinine level before surgery), partial recovery: serum creatinine > 0.5 mg/dl higher than baseline but not dialysis-dependence; non-recovery: patients who remained dialysis dependent
Time Frame
up to 90 days after start of intervention
Title
Mortality
Time Frame
30 days after start of intervention
Title
Mortality
Time Frame
90 days after start of intervention
Title
ICU and hospital stay
Time Frame
up to 90 days after start of intervention (until discharge)
Title
Major adverse kidney events (MAKE)
Description
- major adverse kidney events consisting of mortality, dialysis dependency persistent renal dysfunction (defined as serum creatinine ≥ 2x to baseline value at hospital discharge)
Time Frame
up to 90 days after start of intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients after major surgery who need to be admitted to the ICU Age > 18 years [TIMP-2]*[IGFBP7] ≥ 0.3 4-18 hours after surgery Inserted jugular central venous line and a urinary catheter Written informed consent. At least one additional risk factor for AKI Age > 75 years Critical illness such as ongoing requirement of vasopressor support and/or mechanical ventilation postoperatively Pre-existing chronic kidney disease (eGFR<60ml/min) Intraoperative use of radio contrast agents. Exclusion Criteria: Pregnancy or breastfeeding Pre- existing high stages of chronic kidney disease (stage 4 or 5 i.e. eGFR < 15 ml/ min) Kidney transplant within the last 12 month Known (Glomerulo-) Nephritis, interstitial nephritis or vasculitis Anuria at inclusion time Preexisting AKI Renal replacement therapy (RRT) within the last 90 days Indication for renal replacement at the time of inclusion Participation in another intervention trial that investigates a drug/intervention that affects kidney function Persons held in an institution by legal or official order Persons with any kind of dependency on the investigator or employed by the responsible institution or investigator
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zarbock, MD
Phone
+49-251-8347252
Email
aki@anit.uni-muenster.de
First Name & Middle Initial & Last Name or Official Title & Degree
Meersch, MD
Email
aki@anit.uni-muenster.de
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zarbock, MD
Organizational Affiliation
University Hospital Muenster, Dept. of Anesthesiology, Intensive Care Medicine and Pain Therapy
Official's Role
Study Chair
Facility Information:
Facility Name
Clinical Research Department, Centre Hospitalier Universitaire Brugmann
City
Brussels
Country
Belgium
Individual Site Status
Withdrawn
Facility Name
Centre Hospitalier Universitaire de Angers
City
Angers
Country
France
Individual Site Status
Withdrawn
Facility Name
Centre Hospitalier Universitaire de Clermont-Ferrand
City
Clermont-Ferrand
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Service d´Anesthésie-Réanimation, Hôpital Edouard Herriot, Hospices Civils de Lyon
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Centre Hospitalier Universitaire de Reims
City
Reims
Country
France
Individual Site Status
Not yet recruiting
Facility Name
Department of Anesthesiology and Intensive Care Medicine, University Hospital Augsburg
City
Augsburg
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Department of Anaesthesiology and Intensive Care Medicine, Klinikum Bayreuth GmbH
City
Bayreuth
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Department of Anesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Knappschaftskrankenhaus, Ruhr University Bochum
City
Bochum
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn
City
Bonn
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology, Intensive Care and Pain Medicine, Klinikum Dortmund
City
Dortmund
Country
Germany
Individual Site Status
Completed
Facility Name
Department of Anesthesiology and Intensive Care Medicine, University Hospital "Carl Gustav Carus", Technische Universität Dresden
City
Dresden
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Department of Anesthesiology, University Hospital Düsseldorf, Heinrich-Heine-University Duesseldorf
City
Düsseldorf
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology and Intensive Care Medicine, University Hospital Essen, University Duisburg-Essen
City
Essen
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology, University Medical Center, Georg-August-University
City
Göttingen
Country
Germany
Individual Site Status
Completed
Facility Name
Department of Anesthesiology, Heidelberg University Hospital
City
Heidelberg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Nephrology, Heidelberg University Hospital
City
Heidelberg
Country
Germany
Individual Site Status
Not yet recruiting
Facility Name
Department of Anesthesiology and Intensive Care Medicine, Medical Faculty and University Hospital Cologne, University of Cologne
City
Köln
Country
Germany
Individual Site Status
Withdrawn
Facility Name
Department of Anesthesiology and Intensive Care Medicine, Philipps-University
City
Marburg
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anaesthesiology, Intensive Care and Pain Medicine, University Hospital
City
Münster
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology, Department of Anesthesiology and Critical Care, Franziskus Hospital Münster
City
Münster
Country
Germany
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Eberhard Karls University Tübingen
City
Tübingen
Country
Germany
Individual Site Status
Recruiting
Facility Name
IRCCS Azienda Ospedaliero-Universitaria di Bologna
City
Bologna
Country
Italy
Individual Site Status
Recruiting
Facility Name
Department of Translational Medicine and for Romagna, St. Anne's Archbishop Hospital, University of Ferrara
City
Ferrara
Country
Italy
Individual Site Status
Recruiting
Facility Name
Department of Health Sciences, Section of Anesthesiology, Intensive Care and Pain Medicine, University of Florence; Department of Anesthesia and Intensive Care, Section of Oncological Anesthesia and Intensive care, Azienda Ospedaliero Careggi
City
Firenze
Country
Italy
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology and Intensive Care, IRCCS Humanitas Clinical and Research Hospital
City
Milan
Country
Italy
Individual Site Status
Withdrawn
Facility Name
Santa Chiara Regional Hospital, APSS Trento
City
Trento
Country
Italy
Individual Site Status
Not yet recruiting
Facility Name
Department of Anesthesiology and Intensive Care, San Bortolo Hospital
City
Vicenza
Country
Italy
Individual Site Status
Recruiting
Facility Name
Department of Anaesthesiology, Laboratory of Experimental Intensive Care and Anaesthesiology (L.E.I.C.A.), Amsterdam UMC, Location Academic Medical Centre (AMC), Amsterdam, University of Amsterdam
City
Amsterdam
Country
Netherlands
Individual Site Status
Not yet recruiting
Facility Name
Department of Anaesthesiology and Intensive Care Medicine, Parc de Salut Mar
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology and Critical Care, University Hospital Vall d'Hebron
City
Barcelona
Country
Spain
Individual Site Status
Withdrawn
Facility Name
Hospital de Igualada
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Name
Department of Anesthesia, Hospital Juan Ramon Jimenez
City
Huelva
Country
Spain
Individual Site Status
Withdrawn
Facility Name
Department of Anesthesia and Perioperative Care, Infanta Leonor University Hospital
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Department of Anesthesiology, Hospital Universitario Ramón y Cajal
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital 12 de Octubre
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Hospital Clínico San Carlos de Madrid
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Servicio de Anestesiologia y Reanimación, Hosp. Universitario de La Princesa
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Name
Department of Anaesthesiology and Surgical Critical Care, Hospital Universitario Marqués de Valdecilla
City
Santander
Country
Spain
Individual Site Status
Completed
Facility Name
Hospital Universitario Virgen Macarena
City
Sevilla
Country
Spain
Individual Site Status
Recruiting
Facility Name
Servicio de Anestesiologia, Hospital Universitario y Politécnico La Fe
City
Valencia
Country
Spain
Individual Site Status
Withdrawn
Facility Name
Adult Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV)
City
Lausanne
Country
Switzerland
Individual Site Status
Recruiting
Facility Name
Centre for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Sciences, Queen's University Belfast
City
Belfast
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Intensive Care Unit, Royal Surrey County Hospital
City
Guildford
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Department of Anaesthetics and Critical Care, Harefield Hospital
City
Harefield
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Intensive Care Unit, Royal Liverpool University Hospital
City
Liverpool
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Department of Anesthetics, King's College Hospital, Denmark Hill
City
London
Country
United Kingdom
Individual Site Status
Not yet recruiting
Facility Name
Department of Critical Care, King's College London, Guy's & St Thomas' Hospital
City
London
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Biomarker-guided Intervention to Prevent Acute Kidney Injury

We'll reach out to this number within 24 hrs